Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis Report 2022 to 2023

Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

$ 3999

Japan's Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market is expected to grow from $230 Mn in 2022 to $519 Mn in 2030 with a CAGR of 10.70% for the year 2022-30. PNH has been on the rise in Japan over the past several years in terms of incidence and prevalence. As a result, there is now a considerable market opportunity for producers of PNH medicines. The market is segmented by therapy, diagnostic test, by distribution channel. Some key players in this market include Takeda Pharmaceutical, Astellas Pharma, Otsuka Pharmaceutical, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Akari Therapeutics, Amgen, CSL Behring and Bioverativ.

CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Jigyasu Bhandari

Buy Now

Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Executive Analysis

The Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market size is at around $230 Mn in 2022 and is projected to reach $519 Mn in 2030, exhibiting a CAGR of 10.70% during the forecast period. Healthcare spending per person in Japan has dramatically increased, from $4360 in 2019, which was 10.74% of GDP, to $4478 in 2022, which would be 11.44% of GDP. Because of the country's significant healthcare spending, the healthcare system is sophisticated and intricate. In 2022, there were 12.7 deaths per 1,000 people in Japan.

PNH is more common in Japan than in other affluent nations, with 1 to 10 instances per million people. A rare blood condition called Paroxysmal Nocturnal Hemoglobinuria (PNH) alters how red blood cells are made. Certain blood cells that are vulnerable to being destroyed by the immune system in people with PNH cause a variety of symptoms, such as anaemia, tiredness, and blood clots. PNH is managed by healthcare professionals in Japan using a variety of therapies. Eculizumab, a monoclonal antibody that targets the protein causing red blood cells to be destroyed in PNH, is one such medication. As more people are diagnosed with PNH, the demand for eculizumab, which has been licenced for use in Japan, is anticipated to increase.

Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

PNH has been on the rise in Japan over the past several years in terms of incidence and prevalence. As a result, there is now a considerable market opportunity for producers of PNH medicines. The ageing population of Japan makes it increasingly vulnerable to PNH. The need for PNH therapies is anticipated to rise as the population continues to age. Increased healthcare spending by the Japanese government is anticipated to boost patient access to and cost PNH treatments. Healthcare workers and patients in Japan are becoming more aware of PNH, which is boosting the need for PNH therapies.

Market Restraints

Japan has stringent rules and clearance procedures for new medications, which can cause delays and increased costs for producers. Although PNH is not infrequent in Japan, it is still uncommon compared to other disorders, which can restrict the market for PNH therapies. It may be difficult for innovative medicines to acquire momentum in the market after eculizumab, a monoclonal antibody therapy, was authorised for the treatment of PNH in Japan in 2010.

Competitive Landscape

Key Players

Takeda Pharmaceutical (JP)
Astellas Pharma (JP)
Otsuka Pharmaceutical (JP)
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
Amgen
CSL Behring
Bioverativ

Healthcare Policies and Regulatory Landscape

The Pharmaceuticals and Medical Devices Agency (PMDA), which is a division of the Ministry of Health, Labour, and Welfare (MHLW), is the regulatory body in charge of regulating drug development and approval in Japan. New medications must undergo a rigorous approval procedure in Japan that includes pre-clinical research, clinical testing, and post-marketing monitoring. The universal health coverage model serves as the foundation for the Japanese healthcare system, which is supported by a combination of public and private insurance plans. Drug costs are actively regulated by the government, and in most cases, producers and the government negotiate drug prices.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Segmentation

By Therapy

Medication Therapy
Stem Cell Therapy
Blood Transfusion Therapy

By Diagnostic Tests

CBC
LHD
Bone Marrow Examination
Flow Cytometry

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.